Zobrazeno 1 - 10
of 819
pro vyhledávání: ''
Autor:
Shinjiro Sakamoto, Shintaro Miyamoto, Takeshi Masuda, Satoshi Nakao, Toshihito Otani, Noboru Hattori, Taku Nakashima, Hironobu Hamada, Hiroshi Iwamoto, Yasushi Horimasu, Kazunori Fujitaka, Kakuhiro Yamaguchi
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:857-865
Cytotoxic chemotherapy-induced lung injury is a fatal complication in patients with lung cancer and interstitial lung disease (ILD). We aimed to evaluate the association between hyperglycemia and this form of lung injury in patients with lung cancer
Autor:
Cindy L. O'Bryant, Stefan Zajic, Reginald Ewesuedo, Ashley Milton, Mehmet Akce, Zhi-Yi Zhang, Yongqiang Tang, Peng Pan, Sarina Anne Piha-Paul, Divya Gupta, Anthony B. El-Khoueiry, Patricia L. Judson, Emeline Bacque
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose The purpose of this study is to characterize niraparib pharmacokinetics (PK) and safety in patients with normal hepatic function (NHF) versus moderate hepatic impairment (MHI). Methods Patients with advanced solid tumors were stratified by NH
Publikováno v:
Cancer chemotherapy and pharmacology
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology
Purpose Panitumumab is a human monoclonal antibody targeting the epidermal growth factor receptor for the treatment of wild-type RAS metastatic colorectal cancer (mCRC). Currently, no dedicated clinical studies have evaluated the effect of organ impa
Autor:
Masaji Tani, Shin-ya Morita, Tomohiro Terada, Naoki Yabuta, Daiki Hira, Hiroya Iida, Masatomo Sudou, Satoshi Noda, Akira Andoh, Yoshinori Wakasugi, Takehide Fujimoto
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:281-288
Purpose:We aimed to evaluate exposure-toxicity/efficacy relationship of lenvatinib by determining its target trough concentration for patients with hepatocellular carcinoma (HCC).
Methods:In this retrospective, observational study, 28 HCC patien
Methods:In this retrospective, observational study, 28 HCC patien
Autor:
Yuhki Sakuraoka, Shozo Mori, Takayuki Shiraki, Yukihiro Iso, Takatsugu Matsumoto, Keiichi Kubota, Takamune Yamaguchi, Takayuki Shimizu, Kyung Hwa Park, Taku Aoki
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:109-120
Recently, the number of patients with pancreatic ductal adenocarcinoma (PDAC) who have received both neoadjuvant chemotherapy (NAC) and adjuvant chemotherapy (AC) has been increasing. However, whether adverse events (AEs) during AC influence the prog
Autor:
Keiichiro Ishibashi, Masahito Kotaka, Toru Aoyama, Yasushi Tsuji, Naoki Nagata, Hironaga Satake, Junichi Sakamoto, Masato Nakamura, Koji Oba, Masato Kataoka, Hideyuki Mishima
Publikováno v:
Cancer Chemotherapy and Pharmacology
Background The aim of this study was to evaluate the efficacy and safety of first-line chemotherapy with re-introduction of oxaliplatin (OX) more than 6 months after adjuvant chemotherapy including OX. Methods Stage II/III colon cancer patients with
Autor:
Kaito Shibata, Junichi Kawakami, Satoshi Hirakawa, Hiroyuki Mineta, Seiji Hosokawa, Koji Suzuki, Takafumi Naito
Publikováno v:
Cancer Chemotherapy and Pharmacology. 87(4):555-565
Purpose: Cetuximab inhibits epidermal growth factor receptor (EGFR) signaling in cancer and skin cells, thereby inducing anti-cancer effects and skin disorders. The present study aimed to evaluate the relationships between serum cetuximab and EGFR-re
Autor:
Takahiro Ebata, Yutaka Fujiwara, Shunsuke Kondo, P. Rietschel, Noboru Yamamoto, Tasha N. Sims, Toshio Shimizu, Akihiko Shimomura, Siyu Li, Anne Paccaly, Takafumi Koyama, Satoru Iwasa, Shigehisa Kitano
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Part 1 of this two-part, open-label, Phase 1 study (NCT03233139) assessed the safety, tolerability, pharmacokinetics, immunogenicity, and clinical activity of cemiplimab in Japanese patients with advanced malignancies. Methods Patients receiv
Autor:
Elisabeth Odin, Göran Carlsson, Helena Taflin, Roger Tell, Bengt Gustavsson, Yvonne Wettergren
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose The aim was to explore the correlation between increasing doses of [6R]-5,10-methylenetetrahydrofolate (arfolitixorin) and plasma concentrations of deoxyuridine (dUr) in patients with metastatic colorectal cancer (mCRC), subjected to 5-fluoro
Autor:
Jane B. Trepel, Len Neckers, Jennifer Hedglin, John Lyons, James H. Doroshow, Khanh T. Do, Alona Muzikansky, Susana M. Campos, Kristin Beebe, Percy Ivy, Courtney Gannon, Geoffrey I. Shapiro, Alice P. Chen, Geraldine O'Sullivan Coyne, John L. Hays, Jeffrey G. Supko, Min-Jung Lee, Stephen V. Liu, Tomoko Smyth
Publikováno v:
Cancer Chemother Pharmacol
PURPOSE: We conducted a phase 1 trial of the HSP90 inhibitor onalespib in combination with the CDK inhibitor AT7519, in patients with advanced solid tumors to determine the safety profile and maximally tolerated dose, pharmacokinetics, preliminary an